Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics is a clinical-stage biotech company pursuing a focused drug-development thesis: rare genetic diseases caused by insufficient production of a healthy protein can be treated by using a small molecule called an antisense oligonucleotide to nudge cells into producing more of that protein. The company’s lead candidate is in late-stage trials for Dravet syndrome, a severe and progressive childhood epilepsy. If that drug succeeds, it would be the first disease-modifying medicine approved for this condition. If it fails, the company has no commercial revenue to cushion the blow.

The science: reducing is not always the answer

Many rare genetic diseases are caused by mutations that result in loss of function—a defective gene that produces no protein at all, or a protein that is folded incorrectly and does not work. The classical genetic-disease paradigm has been to replace the missing protein (gene therapy) or to correct the underlying genetic mutation (gene editing). Both are powerful approaches, and both have succeeded in specific contexts.

Stoke pursues a third strategy: the disease is caused not by absence of the gene, but by underproduction of a healthy protein from a single functional copy of the gene. In these cases, the cell is capable of producing the right protein; it is simply producing too little of it. Stoke’s hypothesis is that by using an antisense oligonucleotide—a short synthetic strand of nucleic acid—to modulate how the cell processes the genetic message, it can coax the cell into producing more of the healthy protein. The result would be a cell that produces sufficient protein without needing to repair the gene itself.

This mechanism is called TANGO, for Torsion-Activated Nuclear Gene Output. The details are technical, but the intuition is that the oligonucleotide binds to regulatory regions and alters how the cell reads and expresses the healthy gene, amplifying its output. If the mechanism works, the drug would be taken systemically (by injection or oral administration), reach target cells in the brain or other tissues, and increase protein production continuously.

Dravet syndrome: the lead program

Dravet syndrome is a rare genetic form of epilepsy that emerges in infancy and leads to severe, frequent seizures that are difficult to control with available antiepileptic drugs. It is caused by mutations in the SCN1A gene, which codes for a sodium channel that is critical for controlling electrical activity in neurons. Patients with Dravet have insufficient sodium-channel protein, which means their neurons are hyperexcitable, firing at inappropriate times and triggering seizures.

Current treatment relies on antiepileptic medications that suppress seizure activity, but do not address the underlying deficiency in sodium channels. Many patients continue to have seizures despite maximum tolerated doses of multiple drugs, and the disorder carries significant morbidity and mortality risk.

Stoke’s lead drug, STK-001 (now branded as zorevunersen in partnership discussions), is an antisense oligonucleotide designed to increase production of functional sodium-channel protein in the neurons of Dravet patients. The company has obtained regulatory alignment from the U.S. Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency for a Phase 3 clinical trial called EMPEROR. If EMPEROR shows that zorevunersen reduces seizure frequency meaningfully and safely compared to placebo, and if the regulatory agencies agree, the drug could become the first disease-modifying therapy for Dravet syndrome.

The prize is large. Dravet syndrome affects roughly four to eight thousand patients in the United States and several thousand more in Europe and Japan. If zorevunersen works and is approved, it could become standard of care for newly diagnosed patients, representing a substantial commercial opportunity and a genuine unmet medical need filled.

The partnership model and de-risking

Stoke has not pursued the traditional biotech path of funding all of its development in-house. Instead, the company has entered strategic partnerships with larger pharmaceutical companies to share both the risk and the cost of drug development.

The most important partnership is with Biogen, a large, established biotechnology company with expertise in neurology and a commercial infrastructure for rare diseases. Biogen paid Stoke a $165 million upfront payment in 2024 and will fund development and commercialisation of zorevunersen outside of the United States. Stoke retains U.S. rights and receives milestone payments and royalties based on sales or development progress.

This deal structure de-risks Stoke’s cash position in the near term—the upfront payment buys development time—and transfers much of the development cost and commercial risk to Biogen. The trade-off is that if zorevunersen becomes a blockbuster drug, Stoke forgoes the upside from international sales. But for a small, pure-play development company with no revenue and a single lead program, the partnership is financially sensible: it ensures the development continues even if capital markets freeze, and it brings expertise in patient recruitment and regulatory navigation that Biogen has accumulated over decades.

A second partnership with Acadia Pharmaceuticals funds development of STK-002, an antisense medicine targeting autosomal dominant optic atrophy (ADOA), a genetic eye disease causing progressive vision loss. Acadia paid $60 million upfront and is funding STK-002 development. This deal extends Stoke’s pipeline beyond Dravet syndrome and reduces the company’s single-asset risk.

The pipeline and the binary risk

Outside of zorevunersen and the Acadia partnership, Stoke’s pipeline is underdeveloped. The company has early-stage preclinical programs in a handful of other rare genetic diseases, but nothing approaching the maturity or clinical validation of the lead program.

This is standard for an early-stage biotech company, but it creates a stark risk profile: if zorevunersen fails in Phase 3 (perhaps the drug is not effective, or it has safety issues that emerge only in larger patient populations), Stoke’s stock would likely decline sharply. The company’s value rests almost entirely on the success of one drug. The partnerships with Biogen and Acadia reduce Stoke’s cash burn and provide some diversification, but they do not fully mitigate the concentration risk.

This is not unusual for rare-disease biotechs. The path to profitability in orphan diseases often requires a single drug to succeed, because the total addressable market for any one rare disease is small—there may be only a few thousand patients worldwide. A company that succeeds brings one drug to market, uses the cash flow to fund a second program, and over time builds a portfolio. Until that first drug is approved, the company is highly binary.

Burn rate and the capital question

Like all development-stage biotech companies, Stoke burns cash to fund research, regulatory support, and the costs of running clinical trials. The company’s burn rate—how much cash it spends each quarter—is a critical metric for understanding how long the runway is before the company needs to raise more capital or achieve meaningful revenue.

The Biogen partnership (and to a lesser extent, the Acadia deal) provides runway by shifting some development costs to the partners. Without these partnerships, Stoke would need to raise capital from outside investors—either through venture funding, through the public markets (a secondary offering of stock), or through debt. The existing partnerships are therefore a valuable asset in their own right, not just because of the scientific value of the partnerships themselves.

If zorevunersen enters Phase 3 and the trial progresses on schedule, the Phase 3 timeline is typically two to three years, meaning Stoke may not have a commercial outcome or regulatory decision until 2027 or 2028 at the earliest. The Biogen payment should bridge that gap, but if the trial encounters delays or if the company pursues additional programs faster than originally planned, Stoke may need to raise additional capital before then.

Moat, or lack thereof

Stoke’s competitive advantage, if it has one, is twofold: the intellectual property underlying the TANGO platform and the relationships with large pharma partners who can execute development at scale.

The IP is Stoke’s proprietary method for using antisense oligonucleotides to increase gene expression in rare genetic diseases. If zorevunersen succeeds, the patent portfolio around that approach becomes valuable. Competitors could pursue similar drugs targeting the same mechanism (other companies are active in this space), but they would start from behind Stoke in terms of regulatory experience and clinical data.

The Biogen partnership is valuable less as a moat and more as a de-risking mechanism and a validation of Stoke’s approach. That said, partnerships can be renegotiated or terminated if circumstances change, so they are not permanent competitive advantages.

How to research Stoke as an investment

Understanding Stoke requires deep familiarity with the EMPEROR trial. Track any public press releases or presentations where the company or Biogen discuss trial enrollment, efficacy signals, or safety data. Read the SEC filings, particularly the 10-K, which will detail the trial timeline and any concerns the company discloses about the likelihood of success.

Learn about Dravet syndrome itself—its natural history, the current standard of care, and the patient population. Understanding the disease helps contextualize the market opportunity and the unmet medical need the drug aims to address.

Monitor Stoke’s cash position. The 10-K will disclose cash and equivalents and the company’s estimated burn rate. Calculate the runway: if the company has thirty million dollars and burns five million per quarter, it has roughly six quarters before capital depletion (assuming no new revenue).

Finally, recognise that investing in a preclinical-stage biotech is a bet on a specific clinical outcome. If you believe zorevunersen will succeed in EMPEROR and that Dravet patients will benefit materially from it, Stoke may be attractive. If you have doubts about the mechanism, the trial execution, or the commercial opportunity, the risk is stark: clinical failure can translate to substantial losses. This is a map of how the company and its risk profile work, not an investment recommendation.